Why NeuroSense Therapeutics Ltd.’s (NRSN) Stock Is Down 6.82%
As of Thursday, June 26, NeuroSense Therapeutics Ltd.’s NRSN share price has dipped by 6.82%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer’s disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
Commentary & Analysis
Why NeuroSense Therapeutics Ltd.’s (NRSN) Stock Is Down 9.52%
As of Wednesday, June 25, NeuroSense Therapeutics Ltd.’s NRSN share price has dipped by 9.52%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why NeuroSense Therapeutics Ltd.’s (NRSN) Stock Is Up 6.10%
As of Tuesday, June 24, NeuroSense Therapeutics Ltd.’s NRSN share price has surged by 6.10%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why NeuroSense Therapeutics Ltd.’s (NRSN) Stock Is Down 5.96%
As of Monday, June 23, NeuroSense Therapeutics Ltd.’s NRSN share price has dipped by 5.96%, which has investors questioning if this is right time to buy.Jenna Brashear
Why NeuroSense Therapeutics Ltd.’s (NRSN) Stock Is Down 6.72%
As of Friday, June 13, NeuroSense Therapeutics Ltd.’s NRSN share price has dipped by 6.72%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | NRSN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $12.8 | $257.9 | 8% |
|
| Shares Out (Mil) | 1.3 | 54.3 | 5% |
|
| Institutional Ownership | 3.3% | 92.9% | 4% |
|
| Float (Mil) | 1.2 | 41.4 | 3% |
|
| Beta | 1.58 | 0.95 | 84% |
|
| Avg Daily Volume (000s) | 18 | 674 | 20% |
|
| Price Change (52-week) |
(72.0%) | 51.5% | 10% |
|
| Growth | NRSN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | (31.7%) | (10.1%) | 13% |
|
| EPS (5yr) | 3.2% | 15.8% | 36 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (28.8%) | (15.6%) | 20% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | NRSN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($11) | ($43) | 28% |
|
| EPS (TTM) | ($8.732) | ($1.600) | 5% |
|
| Operating Cash Flow (TTM) (Mil) | ($8) | ($32) | 22% |
|
| Net Cash Flow (TTM) (Mil) | ($3) | $2 | 36% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 9% |
|
| Enterprise Value (Q1) (Mil) | $12 | $174 | 8% |
|
| Valuation | NRSN | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.51 | na |
|
| P/E | na | 19.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | NRSN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 68.9% | na |
|
| Net Margin | na | (72.5%) | na |
|
| ROA | (397.1%) | (47.7%) | 1% |
|
| ROE | na | (54.9%) | na |
|
| Liabilities to Assets | 251.8% | 29.1% | 99% |
|
| F-Score | 1 | 3 | 1% |
|
NeuroSense Therapeutics Ltd. did not pass any screens on 9/25/2026.
